Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Phase 3

Completed

• Conditions: Arthroplasty, Replacement, Hip

• Registration Number: NCT00349180
• Lead Sponsor: Sanofi

Brief Summary

This study is performed to confirm the optimal dose for THR (total hip replacement).

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06
• Study First Submitted: 2006-07-04
• Study First Submitted QC: 2006-07-04
• Study First Posted: 2006-07-06
• Status Verified: 2009-03
• Last Update Submitted: 2009-03-26
• Last Update Posted: 2009-03-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

• Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion Criteria

• Patient with risk of clinical significant bleeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Incidence of VTE

Secondary Outcome Measures

Name	Time	Method
Incidence of bleeding

Trial Locations

Locations (1)

Sanofi-Aventis; 🇯🇵 Tokyo, Japan